ContraFect has revealed its phase 3 clinical trial has failed an interim futility analysis. The inability of the direct lytic agent to beat placebo triggered...
36 months ago

Novel mechanism of action. In July 2020, ContraFect was awarded a grant by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical...
22 months ago

Clinical-stage biotechnology firm ContraFect has commenced a Phase Ib/II clinical trial of exebacase in patients with chronic prosthetic joint...
28 months ago

ContraFect Stock Tanks 75% After Experts Recommend To Stop DISRUPT Trial ... (RTTNews) - Shares of ContraFect Corporation (CFRX) plunged over 75%...
37 months ago

YONKERS, N.Y., Dec. 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on...
32 months ago

Contrafect appoints Lisa Ricciardi as chief operating officer. Contrafect Corp., the Yonkers-based biotechnology company developing protein and antibody...
12 months ago

Exebacase improves clinical outcomes in Staph aureus bacteremia including right-sided endocarditis compared to SOC antibiotics alone.
79 months ago

The ContraFect Corp (NASDAQ: CFRX) stock rose 37.6% on hopes that the firm would not be delisted from the Nasdaq exchange after an appeal.
30 months ago

Studies show that CF-370, by ContraFect, can get around the bacteria's resistance strategies and inhibit resistance to other antibiotics.
39 months ago

How were ContraFect's earnings last quarter? ContraFect Co. (NASDAQ:CFRX) posted its quarterly earnings results on Monday, November, 15th. The biotechnology...
107 months ago